What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com
Aspirin
Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.
Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.
Research evidence, clinical trials and guidelines on Aspirin
The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.
Top results for aspirin
1. Effect of Aspirin on Cancer Incidence and Mortality in Older Adults Full Text available with Trip Pro
Effect of Aspirin on Cancer Incidence and Mortality in Older Adults Effect of Aspirin on Cancer Incidence and Mortality in Older Adults - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Show account info Close Account Logged in as: username Search: Search Save Email Send to Display (...) Format Share Permalink Copy Page navigation J Natl Cancer Inst Actions . 2021 Mar 1;113(3):258-265. doi: 10.1093/jnci/djaa114. Effect of Aspirin on Cancer Incidence and Mortality in Older Adults , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, Victoria, Australia. 2 The Walter & Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia; and Department of Medical
2021 EvidenceUpdates
2. Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS
of the Oral Thrombin Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid in Patients With Embolic Stroke of Undetermined Source) were included. The rate of recurrent stroke (primary end point) and ischemic stroke was reported for patients with and without baseline PFO. A meta-analysis comparing the effects of anticoagulant and antiplatelet therapy on ischemic stroke in patients with PFO was updated to include RE-SPECT ESUS. Results: PFO was present in 680 of 5388 (12.6%) patients with documented (...) Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19
2021 EvidenceUpdates
3. Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin Full Text available with Trip Pro
Stroke or Transient Ischemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death) trial, we randomized patients with a noncardioembolic, nonsevere ischemic stroke, or high-risk transient ischemic attack to ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2-30) or placebo added to aspirin (300-325 mg on day 1 followed by 75-100 mg daily for days 2-30) within 24 hours of symptom onset. The present paper reports a prespecified analysis in patients (...) Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving
2021 EvidenceUpdates
4. Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review
Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest (...) of print. Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review , , Affiliations Expand Affiliations 1 School of Medicine, Faculty of Medicine, Taipei Medical University, Taipei, Taiwan. 2 Graduate Institute of Clinical Medicine, Collage of Medicine, Taipei Medical University, Taipei, Taiwan. 3 Division of Hematology Oncology, Department of Pediatrics, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan jlwang@w.tmu.edu.tw. 4 Department
2020 EvidenceUpdates
5. Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG): A Randomized, Double-Blind, Placebo-Controlled Trial
Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG): A Randomized, Double-Blind, Placebo-Controlled Trial Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG): A Randomized, Double-Blind, Placebo-Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage (...) Display options Format Share Permalink Copy Page navigation Circulation Actions . 2020 Nov 10;142(19):1799-1807. doi: 10.1161/CIRCULATIONAHA.120.050749. Epub 2020 Aug 31. Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG): A Randomized, Double-Blind, Placebo-Controlled Trial , # , # , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Cardiology (L.M.W., P.W.A.J
2020 EvidenceUpdates
6. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) navigation Eur Heart J Actions . 2020 Oct 1;41(37):3533-3545. doi: 10.1093/eurheartj/ehaa670. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Cardiology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA. 2 Department of Cardiology
2020 EvidenceUpdates
7. Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. (Abstract)
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. The effect of single as compared with dual antiplatelet treatment on bleeding and thromboembolic events after transcatheter aortic-valve implantation (TAVI) in patients who do not have an indication for long-term anticoagulation has not been well studied.In a randomized, controlled trial, we assigned a subgroup of patients who were undergoing TAVI and did not have an indication for long-term anticoagulation (...) , in a 1:1 ratio, to receive aspirin alone or aspirin plus clopidogrel for 3 months. The two primary outcomes were all bleeding (including minor, major, and life-threatening or disabling bleeding) and non-procedure-related bleeding over a period of 12 months. Most bleeding at the TAVI puncture site was counted as non-procedure-related. The two secondary outcomes were a composite of death from cardiovascular causes, non-procedure-related bleeding, stroke, or myocardial infarction (secondary composite 1
2020 NEJM
8. In established atherosclerosis, P2Y12 inhibitor vs. aspirin monotherapy reduces MI but not stroke or mortality. (Abstract)
In established atherosclerosis, P2Y12 inhibitor vs. aspirin monotherapy reduces MI but not stroke or mortality. Chiarito M, Sanz-Sánchez J, Cannata F, et al. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet. 2020;395;1487-95. 32386592.
2020 Annals of Internal Medicine
9. In AF with recent ACS or PCI, apixaban improved 30-day outcomes vs. VKAs; aspirin effects varied vs. placebo. (Abstract)
In AF with recent ACS or PCI, apixaban improved 30-day outcomes vs. VKAs; aspirin effects varied vs. placebo. Alexander JH, Wojdyla D, Vora AN, et al. Risk/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS. Circulation. 2020;141:1618-27. 32223444.
2020 Annals of Internal Medicine
10. Major bleeding risk with non-vitamin K antagonist oral anticoagulant vs. aspirin in heart failure: network meta-analysis Full Text available with Trip Pro
daily increased the risk of major bleeding and intracranial haemorrhage compared with aspirin, while apixaban at a dose of 5 mg twice daily conferred comparative risk. Direct RCTs of certain NOAC vs. acetylsalicylic acid (ASA) in sinus rhythm‐HF patients would be worth undertaking if there was suggestive evidence of a less incremental bleeding risk of certain NOACs in the HF population. The incremental bleeding risk in HF patients can usefully be evaluated in both HF patients in sinus rhythm and HF (...) Register of Controlled Clinical Trials, and from 1966 to 6 November 2019 using the search terms: heart failure or cardiac failure or heart decompensation or myocardial failure or congestive heart failure AND novel oral anticoagulants or non‐vitamin K antagonist oral anticoagulants or direct oral anticoagulants or dabigatran or rivaroxaban or apixaban or edoxaban or warfarin or coumadin or vitamin K antagonist or aspirin or acetylsalicylic acid or ASA AND major bleeding or intracranial hemorrhage
2020 ESC heart failure
11. SMFM Special Statement: Checklists for preeclampsia risk-factor screening to guide recommendations for prophylactic low-dose aspirin
SMFM Special Statement: Checklists for preeclampsia risk-factor screening to guide recommendations for prophylactic low-dose aspirin Society for Maternal-Fetal Medicine Special Statement: Checklists for preeclampsia risk-factor screening to guide recommendations for prophylactic low-dose aspirin - American Journal of Obstetrics & Gynecology Go search , PB7-B11, September 01, 2020 Powered By Mendeley Share on Society for Maternal-Fetal Medicine Special Statement: Checklists for preeclampsia risk (...) -factor screening to guide recommendations for prophylactic low-dose aspirin SMFM Patient Safety and Quality Committee ∗ C. Andrew Combs Affiliations Patient Safety and Quality Improvement Committee, Society for Maternal-Fetal Medicine, Washington, DC Douglas M. Montgomery Affiliations Patient Safety and Quality Improvement Committee, Society for Maternal-Fetal Medicine, Washington, DC Published: June 14, 2020 DOI: In pregnant individuals with risk factors for preeclampsia, prophylactic low-dose
2020 Society for Maternal-Fetal Medicine
12. The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y 12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard (...) navigation Circulation Actions . 2020 Aug 11;142(6):538-545. doi: 10.1161/CIRCULATIONAHA.120.046251. Epub 2020 Jun 19. The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y 12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis , , Affiliations Expand Affiliation 1 TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA. PMID: 32551860 DOI: Item in Clipboard The Safety and Efficacy of Aspirin
2020 EvidenceUpdates
13. AORN, ASA, and APSF Clarification of Powered Air-Purifying Respirator (PAPR) Use in the Operating Room and Other Procedural Areas in Which Sterile Fields are Present
AORN, ASA, and APSF Clarification of Powered Air-Purifying Respirator (PAPR) Use in the Operating Room and Other Procedural Areas in Which Sterile Fields are Present AORN, ASA, and APSF Clarification of Powered Air-Purifying Respirator (PAPR) Use in the Operating Room and Other Procedural Areas in Which Sterile Fields are Present | American Society of Anesthesiologists (ASA) Menu Menu Close Guidelines, Statements, Clinical Resources Back Guidelines, Statements, Clinical Resources ASA Community (...) Back ASA Community Advocacy & ASAPAC Back Advocacy & ASAPAC Education and Career Back Education and Career Events Back Events In the Spotlight Back In the Spotlight Podcasts Back Podcasts Quality and Practice Management Back Quality and Practice Management Research and Publications Back Research and Publications Member Center Back Member Center About ASA Back About ASA News June 30, 2020 AORN, ASA, and APSF Clarification of Powered Air-Purifying Respirator (PAPR) Use in the Operating Room and Other
2020 American Society of Anesthesiologists
14. ASA-APSF Joint Statement on the Necessity of Wearing Face Masks in Public Full Text available with Trip Pro
ASA-APSF Joint Statement on the Necessity of Wearing Face Masks in Public ASA-APSF Joint Statement on the Necessity of Wearing Face Masks in Public Menu Menu Close Guidelines, Statements, Clinical Resources Back Guidelines, Statements, Clinical Resources ASA Community Back ASA Community Advocacy & ASAPAC Back Advocacy & ASAPAC Education and Career Back Education and Career Events Back Events In the Spotlight Back In the Spotlight Podcasts Back Podcasts Quality and Practice Management Back (...) Quality and Practice Management Research and Publications Back Research and Publications Member Center Back Member Center About ASA Back About ASA News June 30, 2020 ASA-APSF Joint Statement on the Necessity of Wearing Face Masks in Public (PDF) The American Society of Anesthesiologists (ASA) and the Anesthesia Patient Safety Foundation (APSF) strongly urge all persons over the age of 2 to cover their nose and mouth with a cloth or disposable face mask while in public. Recent studies have found
2020 American Society of Anesthesiologists
15. Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial
Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving (...) in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial , , , , , , , , , , , , , Affiliations Expand Affiliations 1 School of Public Health & Preventive Medicine, Monash University Faculty of Medicine Nursing and Health Sciences, Melbourne, Victoria, Australia suzanne.mahady@monash.edu. 2 Gastroenterology, Melbourne Health, Parkville, Victoria, Australia. 3 HealthPartners Institute, Minneapolis, Minnesota, USA. 4 Clinical and Translational Epidemiology Unit
2020 EvidenceUpdates
16. Aspirin (single dose) for perineal pain in the early postpartum period. (Abstract)
with newborn care and the establishment of breastfeeding. Aspirin has been used in the management of postpartum perineal pain, and its effectiveness and safety should be assessed. This is an update of the review, last published in 2017.To determine the effects of a single dose of aspirin (acetylsalicylic acid), including at different doses, in the relief of acute postpartum perineal pain.For this update, we searched the Cochrane Pregnancy and Childbirth's Trials Register (4 October 2019 (...) Aspirin (single dose) for perineal pain in the early postpartum period. Perineal trauma, due to spontaneous tears, surgical incision (episiotomy), or in association with operative vaginal birth, is common after vaginal birth, and is often associated with postpartum perineal pain. Birth over an intact perineum may also lead to perineal pain. There are adverse health consequences associated with perineal pain for the women and their babies in the short- and long-term, and the pain may interfere
2020 Cochrane
17. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. Full Text available with Trip Pro
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. Trials have evaluated the use of clopidogrel and aspirin to prevent stroke after an ischemic stroke or transient ischemic attack (TIA). In a previous trial, ticagrelor was not better than aspirin in preventing vascular events or death after stroke or TIA. The effect of the combination of ticagrelor and aspirin on prevention of stroke has not been well studied.We conducted a randomized, placebo-controlled, double-blind (...) trial involving patients who had had a mild-to-moderate acute noncardioembolic ischemic stroke, with a National Institutes of Health Stroke Scale (NIHSS) score of 5 or less (range, 0 to 42, with higher scores indicating more severe stroke), or TIA and who were not undergoing thrombolysis or thrombectomy. The patients were assigned within 24 hours after symptom onset, in a 1:1 ratio, to receive a 30-day regimen of either ticagrelor (180-mg loading dose followed by 90 mg twice daily) plus aspirin (300
2020 NEJM
18. The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease Full Text available with Trip Pro
: 10.1161/CIR.0000000000000880. Epub 2020 Jul 6. Circulation. 2020. PMID: 32628554 No abstract available. Abstract Background: Rivaroxaban 2.5 mg twice daily plus acetylsalicylic acid (aspirin; ASA) 100 mg reduced the risk of cardiovascular events as compared with ASA monotherapy in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) but increased the risk of major bleedings. Analysis of net clinical benefit (NCB) is of key clinical relevance and represents (...) The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily
2020 EvidenceUpdates
19. Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial
Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National (...) RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation JAMA Psychiatry Actions . 2020 Jun 3;e201214. doi: 10.1001/jamapsychiatry.2020.1214. Online ahead of print. Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 The Institute for Mental and Physical Health and Clinical Translation Strategy Research Centre, Deakin University School of Medicine, Geelong
2020 EvidenceUpdates
20. Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis Full Text available with Trip Pro
Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis | Research Square Browse Tools & Services Your Cart See the published version of this article at . This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting (...) preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis Juli Lin, Jian-xian Lin, Chao-hui Zheng, Ping Li, Jian-wei Xie, Jia-bin Wang, Jun Lu, Qi-yue Chen, Long-Long Cao, Mi Lin, Chang-ming Huang Juli Lin Xiehe Affiliated Hospital